Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HMPL-A251 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| HMPL-A251 | DRUG | Six dose cohorts are planned for the Dose Escalation phase; at least three participants with solid tumors will be enrolled in each dose cohort. Bayesian optimal interval design with backfill (BF-BOIN, Zhao, 2023) will be used to guide dose escalation and determine the MTD and/or RDE of HMPL-A251. All study participants will receive HMPL-A251 as IV infusion until PD, intolerable toxicity, or other protocol-specified criteria for ending study treatment, whichever occurs first. |
HMPL-A251 is an investigational small molecule being studied for the treatment of advanced or metastatic HER2-expressing solid tumors in adults. It is currently in clinical development and has not been approved by regulatory authorities.
HMPL-A251 targets HER2-expressing solid tumors. It is being evaluated in patients with advanced or metastatic cancers that express the HER2 protein, a common target in oncology drug development.
HMPL-A251 is being developed by HUTCHMED (China) Limited, a biopharmaceutical company listed on the stock exchange under the ticker HCM.
HMPL-A251 is in Phase 2 clinical development. It is being studied in a Phase 1/2a trial that is currently recruiting participants, meaning it is still investigational and not yet approved.
HMPL-A251 is being studied in a Phase 1/2a clinical trial with the identifier NCT07228247. This trial is recruiting 147 participants with advanced or metastatic HER2-expressing solid tumors and is currently active.